Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Statistics
Share Statistics
Foghorn Therapeutics has 55.61M shares outstanding. The number of shares has increased by 0.51% in one year.
| Shares Outstanding | 55.61M |
| Shares Change (YoY) | 0.51% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 64.28% |
| Shares Floating | 27.84M |
| Failed to Deliver (FTD) Shares | 109 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 995.69K, so 1.79% of the outstanding shares have been sold short.
| Short Interest | 995.69K |
| Short % of Shares Out | 1.79% |
| Short % of Float | 2.81% |
| Short Ratio (days to cover) | 7.45 |
Valuation Ratios
The PE ratio is -2.99 and the forward PE ratio is -4. Foghorn Therapeutics's PEG ratio is 0.09.
| PE Ratio | -2.99 |
| Forward PE | -4 |
| PS Ratio | 11.46 |
| Forward PS | 2.4 |
| PB Ratio | -5.69 |
| P/FCF Ratio | -2.56 |
| PEG Ratio | 0.09 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Foghorn Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.73, with a Debt / Equity ratio of -0.82.
| Current Ratio | 3.73 |
| Quick Ratio | 3.73 |
| Debt / Equity | -0.82 |
| Debt / EBITDA | -0.38 |
| Debt / FCF | -0.37 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $201.8K |
| Profits Per Employee | $-773.39K |
| Employee Count | 112 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -10.17% in the last 52 weeks. The beta is 3.16, so Foghorn Therapeutics's price volatility has been higher than the market average.
| Beta | 3.16 |
| 52-Week Price Change | -10.17% |
| 50-Day Moving Average | 4.35 |
| 200-Day Moving Average | 6.19 |
| Relative Strength Index (RSI) | 63.31 |
| Average Volume (20 Days) | 136.03K |
Income Statement
In the last 12 months, Foghorn Therapeutics had revenue of 22.6M and earned -86.62M in profits. Earnings per share was -1.58.
| Revenue | 22.6M |
| Gross Profit | 22.6M |
| Operating Income | -102.68M |
| Net Income | -86.62M |
| EBITDA | -97.17M |
| EBIT | -100.28M |
| Earnings Per Share (EPS) | -1.58 |
Balance Sheet
The company has 55.45M in cash and 37.13M in debt, giving a net cash position of 18.32M.
| Cash & Cash Equivalents | 55.45M |
| Total Debt | 37.13M |
| Net Cash | 18.32M |
| Retained Earnings | -558.18M |
| Total Assets | 283.98M |
| Working Capital | 182.61M |
Cash Flow
In the last 12 months, operating cash flow was -100.41M and capital expenditures -906K, giving a free cash flow of -101.31M.
| Operating Cash Flow | -100.41M |
| Capital Expenditures | -906K |
| Free Cash Flow | -101.31M |
| FCF Per Share | -1.85 |
Margins
Gross margin is 100%, with operating and profit margins of -454.31% and -383.24%.
| Gross Margin | 100% |
| Operating Margin | -454.31% |
| Pretax Margin | -383.24% |
| Profit Margin | -383.24% |
| EBITDA Margin | -429.9% |
| EBIT Margin | -454.31% |
| FCF Margin | -448.24% |
Dividends & Yields
FHTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for FHTX is $11.5, which is 145.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.5 |
| Price Target Difference | 145.7% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -2.64 |
| Piotroski F-Score | 1 |